secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-07-27T20:06:43+00:00
Accession:  0000885725-26-000049
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific approves 2026 restructuring plan with $700M-$800M pre-tax charges
--------------------------------------------------------------------------------

- Board approved 2026 Restructuring Plan on July 21, 2026; expected to be substantially completed by end of 2029.
- Estimated total pre-tax charges of $700M-$800M, with $600M-$700M in cash outlays; annual pre-tax expense reduction of ~$500M.
- Charges include transfer costs ($300M-$350M), termination benefits ($275M-$300M), and other costs ($125M-$150M).
- Headcount reductions expected, but new jobs created in growth areas; savings to be reinvested in strategic growth initiatives.
- Activities include supply chain optimization, transferring production lines, and functional transformation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000049/0000885725-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000049/bsx-20260721.htm
  HTML page:      https://secwatch.observer/filing/0000885725-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer